Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00161642 | Study Evaluating CMD-193 in Advanced Malignant Solid Tumors | PHASE1 | COMPLETED | 54 | — | — | Nov 1, 2004 | Jul 1, 2007 | Sep 10, 2009 | 3 | United States |
| Name | Type | Description |
|---|---|---|
| CMD-193 | DRUG | - |
Inclusion Criteria: * Histologically confirmed malignant solid tumor that has progressed following standard therapy, or for which no standard effective treatment is available * Tumor expression of Lewis Y antigen ( \> or = 20% tumor cells positive for Lewis Y by immunohistochemistry assay) * Easter...